Ocular Therapeutix
OCUL
76 hedge funds and large institutions have $146M invested in Ocular Therapeutix in 2016 Q4 according to their latest regulatory filings, with 19 funds opening new positions, 25 increasing their positions, 23 reducing their positions, and 13 closing their positions.
96% more call options, than puts
Call options by funds: $1.29M | Put options by funds: $658K
69.91% more ownership
Funds ownership: 0% → 69.91% (+70%)
46% more first-time investments, than exits
New positions opened: 19 | Existing positions closed: 13
13% more capital invested
Capital invested by funds: $128M → $146M (+$17.2M)
6% more funds holding
Funds holding: 72 → 76 (+4)
9% more repeat investments, than reductions
Existing positions increased: 25 | Existing positions reduced: 23
0% more funds holding in top 10
Funds holding in top 10: 3 → 3 (0)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Jennison Associates
New York
|
+$1.65M |
| 2 |
SSA
Schonfeld Strategic Advisors
New York
|
+$1.61M |
| 3 |
Renaissance Technologies
New York
|
+$1.13M |
| 4 |
DAM
Deltec Asset Management
New York
|
+$892K |
| 5 |
BIT
BlackRock Institutional Trust
San Francisco,
California
|
+$782K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Fidelity Investments
Boston,
Massachusetts
|
-$6.94M |
| 2 |
SHI
SV Health Investors
Boston,
Massachusetts
|
-$2.54M |
| 3 |
JMPWA
JP Morgan Private Wealth Advisors
San Francisco,
California
|
-$2.31M |
| 4 |
BFA
BlackRock Fund Advisors
San Francisco,
California
|
-$1.94M |
| 5 |
Morgan Stanley
New York
|
-$1.9M |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
TDC
76
Thompson Davis & Co
Richmond,
Virginia
| $1K | – | – | – |
|
|
JMPWA
77
JP Morgan Private Wealth Advisors
San Francisco,
California
| – | -$2.31M | -336,320 | Closed |
|
78
Federated Hermes
Pittsburgh,
Pennsylvania
| – | -$1.8M | -261,700 | Closed |
|
|
PC
79
Polar Capital
London,
United Kingdom
| – | -$395K | -57,500 | Closed |
|
|
SM
80
Sabby Management
Miami Beach,
Florida
| – | -$262K | -38,100 | Closed |
|
81
Swiss National Bank
Zurich,
Switzerland
| – | -$131K | -19,000 | Closed |
|
82
ProShare Advisors
Bethesda,
Maryland
| – | -$120K | -17,423 | Closed |
|
|
VKH
83
Virtu KCG Holdings
New York
| – | -$92K | -13,414 | Closed |
|
|
BG
84
BlackRock Group
London,
United Kingdom
| – | -$90K | -13,142 | Closed |
|
85
VOYA Investment Management
Atlanta,
Georgia
| – | -$75 | -10,866 | Closed |
|
|
ST
86
Spot Trading
Chicago,
Illinois
| – | -$45K | -6,600 | Closed |
|
87
Canada Life
Winnipeg,
Manitoba, Canada
| – | -$42K | -6,146 | Closed |
|
|
AG
88
Advisor Group
Phoenix,
Arizona
| – | -$12K | -1,800 | Closed |
|
|
TRCT
89
Tower Research Capital (TRC)
New York
| – | -$9K | -1,397 | Closed |
|
OCUL Hedge Fund Activity: Q4 2016 in Review
76 of the 4,000 institutional investors tracked by Wall St. Rank reported a position in Ocular Therapeutix (OCUL) for Q4 2016, worth a combined $146M — up 13% from $128M a quarter earlier.
Buyers outnumbered sellers: 19 funds opened new OCUL positions and 13 closed out — a net gain of 6 holders — while 25 added to existing stakes and 23 trimmed.
The largest buyer was Jennison Associates, adding an estimated $1.65M. The largest seller was Fidelity Investments, cutting an estimated $6.94M.
- 76 institutional investors held Ocular Therapeutix (OCUL) as of Q4 2016, up from 72 in Q3 2016.
- Funds reported $146M of Ocular Therapeutix stock for Q4 2016, up 13% quarter-over-quarter.
- 19 funds opened new Ocular Therapeutix positions in Q4 2016 and 13 closed out, a net change of +6 holders.
- The largest Ocular Therapeutix buyer in Q4 2016 was Jennison Associates, an estimated $1.65M added.
- The largest Ocular Therapeutix seller in Q4 2016 was Fidelity Investments, an estimated $6.94M sold.
Based on aggregated 13F filings for Q4 2016.